Patents Assigned to Amgen
  • HUMAN ANTI-IFN-GAMMA NEUTRALIZING ANTIBODIES AS SELECTIVE IFN-GAMMA PATHWAY INHIBITORS
    Publication number: 20080107655
    Abstract: This invention provides antibodies that interact with or bind to human interferon-gamma (IFN-?) and methods for treating IFN-? mediated diseases by administering a pharmaceutically effective amount of antibodies to IFN-?. Methods of detecting the amount of IFN-? in a sample using antibodies to IFN-? are also provided.
    Type: Application
    Filed: December 21, 2007
    Publication date: May 8, 2008
    Applicants: Amgen Inc., Medarex, Inc.
    Inventors: Andrew Welcher, Hilary Chute, Yue-Sheng Li, Haichun Huang
  • Aryl sulfonamide compounds and uses related thereto
    Patent number: 7365075
    Abstract: The present invention provides Aryl Sulfonamide Compounds having the formula: and prodrugs or pharmaceutically acceptable salts or prodrugs thereof. The Aryl Sulfonamide Compounds are useful for treating diabetes, obesity, and other diseases and disorders.
    Type: Grant
    Filed: December 20, 2004
    Date of Patent: April 29, 2008
    Assignee: Amgen Inc.
    Inventors: Michael R. DeGraffenreid, Xiao He, Jay P. Powers, Daqing Sun, Xuelei Yan
  • Antibodies to OPGL
    Patent number: 7364736
    Abstract: Antibodies that interact with osteoprotegerin ligand (OPGL) are described. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are described. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are described.
    Type: Grant
    Filed: June 25, 2002
    Date of Patent: April 29, 2008
    Assignees: Amgen Inc., Amgen Fremont Inc.
    Inventors: William J. Boyle, Francis H. Martin, Jose R. Corvalan, C. Geoffrey Davis
  • Methods of treating stroke
    Publication number: 20080095760
    Abstract: A method is provided for the localized intravascular administration of a fibrinolytic metalloproteinase to a human subject in amounts that are both safe and effective to lyse an occluding fibrin-containing blood clot, while also avoiding the neutralizing effects of ?2-macroglobulin in the circulating blood. A method is also provided for the treatment of a blood clot in, around or attached to an indwelling vascular access device. A method for restoring patency and function of an indwelling vascular access device is also provided.
    Type: Application
    Filed: November 13, 2007
    Publication date: April 24, 2008
    Applicant: Amgen Inc.
    Inventor: Christopher Toombs
  • Methods for treating atherosclerosis
    Publication number: 20080096900
    Abstract: The invention provides compounds, pharmaceutical compositions and methods for treating atherosclerosis, inflammation, thrombosis and other conditions and for decreasing or prevention of accumulation of cholesterol in a subject by modifying LCAT polypeptide.
    Type: Application
    Filed: June 26, 2007
    Publication date: April 24, 2008
    Applicant: Amgen Inc.
    Inventors: Frank Kayser, Marc LaBelle, Bei Shan, Jian Zhang, Mingyue Zhou
  • Dihydronaphthalene compounds, compositions, uses thereof, and methods for synthesis
    Patent number: 7361789
    Abstract: The present invention relates to novel dihydronaphthalene compounds, compositions, methods for using the same, and processes for preparing the same. The present invention also relates to novel total synthesis approaches for preparing these compounds. In addition, the present invention relates to methods of producing quantities of isomers of these compounds and separating and purifying them using chiral separation techniques. The present invention also relates to methods of producing quantities of a single isometric compound without the need for chiral separation techniques.
    Type: Grant
    Filed: July 27, 2005
    Date of Patent: April 22, 2008
    Assignee: Amgen Inc.
    Inventors: Qi Yan, Carlos Orihuela, Bo Shen, Ying Chen, Xin Wang, John Ng, Ruizhi Ji, Pengzu Zhou
  • Heterocyclic GPR40 Modulators
    Publication number: 20080090840
    Abstract: The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula I: where the definitions of the variables are provided herein. The present invention also provides compositions that include, and methods for using, the compounds in preparing medicaments and for treating metabolic disorders such as, for example, type II diabetes.
    Type: Application
    Filed: September 6, 2007
    Publication date: April 17, 2008
    Applicant: Amgen Inc.
    Inventors: Hilary Beck, Paul Dransfield, Zice Fu, Jonathan Houze, Xian Yun Jiao, Todd Kohn, SuJen Lai, Jinqian Liu, Jiwen Liu, Zhihua Ma, Michael Schmitt, Rajiv Sharma, Wang Shen, Marc Vimolratana, Yingcai Wang, Zhongyu Wang
  • Beta-like glycoprotein hormone polypeptide and heterodimer
    Patent number: 7358341
    Abstract: Novel ?10 polypeptides and heterodimers thereof, and nucleic acid molecules encoding the same are disclosed. The invention also provides vectors, host cells, selective binding agents, and methods for producing ?10 polypeptides and heterodimeric forms thereof, specifically ?2/?10. Also provided for are methods for the treatment, diagnosis, amelioration, or prevention of diseases with ?10 polypeptides and ?2/?10 heterodimers or their respective binding agents.
    Type: Grant
    Filed: May 28, 2003
    Date of Patent: April 15, 2008
    Assignee: Amgen Inc.
    Inventors: Christopher J. R. Paszty, Jin Cao, Dimitry M. Danilenko, Jianhua Gong, David C. Hill
  • Pyrrolo[2,3-d]pyrimidines that modulate ACK1 activity
    Patent number: 7358250
    Abstract: Compounds that modulate the action of ACK1 and LCK, and related compositions methods for treating ACK1- and LCK-mediated diseases are described. In one aspect, the compounds have the general structure: where the values of the substituents are provided herein.
    Type: Grant
    Filed: June 29, 2005
    Date of Patent: April 15, 2008
    Assignee: Amgen Inc.
    Inventors: Christopher N. Farthing, Paul Faulder, Alexander D. Frenkel, Martin J. Harrison, Xianyun Jiao, Frank Kayser, David J. Kopecky, Jinqian Liu, Sarah E. Lively, Rajiv Sharma, Stephen J. Shuttleworth
  • Bis-aryl thiazole derivatives
    Patent number: 7358267
    Abstract: Compounds, compositions and methods are provided that are useful in the treatment or prevention of a condition or disorder mediated by an uncoupling protein. In particular, the compounds of the invention modulate the expression and/or activity of UCP3.
    Type: Grant
    Filed: June 27, 2002
    Date of Patent: April 15, 2008
    Assignee: Amgen Inc.
    Inventors: M. Catherine Amaral, Jin-Long Chen, Juan C. Jaen, David N. Johnston, Paul Rafferty
  • Pyrazole compounds and uses related thereto
    Patent number: 7354938
    Abstract: Substituted pyrazoles are provided that are useful for the treatment of, for example, diabetes, obesity and metabolic syndrome.
    Type: Grant
    Filed: March 18, 2005
    Date of Patent: April 8, 2008
    Assignee: Amgen Inc.
    Inventors: Hiroyuki Goto, Makoto Kakutani, Jun Nishiu, Yasuhiro Ohe, Jay P. Powers, Shinji Yata, Hua Tu
  • Antibody-induced apoptosis
    Patent number: 7354583
    Abstract: Anti-Her2 antibodies which induce apoptosis in Her2 expressing cells are disclosed. The antibodies are used to “tag” Her2 overexpressing tumors for elimination by the host immune system. Also disclosed are hybridoma cell lines producing the antibodies, methods for treating cancer using the antibodies, and pharmaceutical compositions.
    Type: Grant
    Filed: November 27, 2001
    Date of Patent: April 8, 2008
    Assignee: Amgen, Inc.
    Inventors: Tsutomu Arakawa, Yoshiko Kita
  • Thiadiazole compounds and methods of use
    Patent number: 7354944
    Abstract: The invention relates to thiadiazole compounds useful for treating diseases mediated by protein kinase B (PKB). The invention also relates to the therapeutic use of such thiadiazole compounds and compositions thereof in treating disease states associated with abnormal cell growth, cancer, inflammation, and metabolic disorders.
    Type: Grant
    Filed: October 18, 2005
    Date of Patent: April 8, 2008
    Assignee: Amgen Inc.
    Inventors: Qingping Zeng, Guomin Yao, George Erich Wohlhieter, Vellarkad N. Viswanadhan, Andrew Tasker, James Thomas Rider, Holger Monenschein, Celia Dominguez, Matthew Paul Bourbeau
  • Nucleic acids encoding fibroblast growth factor receptor-like proteins and uses thereof
    Patent number: 7348162
    Abstract: The present invention provides Fibroblast Growth Factor Receptor-Like (FGFR-L) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing FGFR-L polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with FGFR-L polypeptides.
    Type: Grant
    Filed: March 22, 2001
    Date of Patent: March 25, 2008
    Assignee: Amgen Inc.
    Inventors: Christiaan M. Saris, Sharon X. Mu, Min Xia, Thomas Charles Boone, Todd Covey
  • Fibroblast Growth Factor-Like Polypeptides
    Publication number: 20080071065
    Abstract: The present invention provides novel Fibroblast Growth Factor-like (FGF-like) polypeptides and nucleic acid molecules encoding the same. The invention also provides vectors, host cells, antibodies and methods for producing FGF-like polypeptides. Also provided for are methods for the diagnosis and treatment of diseases associated with FGF-like polypeptides.
    Type: Application
    Filed: April 11, 2007
    Publication date: March 20, 2008
    Applicant: AMGEN, INC.
    Inventors: Arlen Thomason, Benxian Liu, Dimitry Danilenko
  • Fibroblast Growth Factor-Like Polypeptides
    Publication number: 20080071066
    Abstract: The present invention provides novel Fibroblast Growth Factor-like (FGF-like) polypeptides and nucleic acid molecules encoding the same. The invention also provides vectors, host cells, antibodies and methods for producing FGF-like polypeptides. Also provided for are methods for the diagnosis and treatment of diseases associated with FGF-like polypeptides.
    Type: Application
    Filed: April 11, 2007
    Publication date: March 20, 2008
    Applicant: AMGEN, INC.
    Inventors: Arlen Thomason, Benxian Liu, Dimitry Danilenko
  • ANTAGONISTS AND AGONISTS OF LDCAM AND METHODS OF USE
    Publication number: 20080064104
    Abstract: The invention pertains to agonists and antagonists of LDCAM and methods of treating disease and infection by administering one or more LDCAM antagonists or agonists. This abstract is provided for the sole purpose of enabling the reader to quickly ascertain the subject matter of the technical disclosure and is not intended to be used to interpret or limit the scope or meaning of the claims.
    Type: Application
    Filed: September 7, 2007
    Publication date: March 13, 2008
    Applicant: Amgen Inc.
    Inventors: Laurent Galibert, Wei Yan
  • Novel DKR polypeptides
    Publication number: 20080057540
    Abstract: Disclosed are nucleic acid molecules encoding novel DKR polypeptides. Also disclosed are methods of preparing the nucleic acid molecules and polypeptides, and methods of using these molecules.
    Type: Application
    Filed: August 14, 2007
    Publication date: March 6, 2008
    Applicant: AMGEN INC.
    Inventors: Michael Bass, John Sullivan, Lars Theill, Daguang Wang
  • Methods for the treatment of thrombosis
    Publication number: 20080058256
    Abstract: A fibrinolytically active metalloproteinase polypeptide (called “novel acting thrombolytic”) which is useful for blood clot lysis in vivo and methods and materials for its production by recombinant expression are described.
    Type: Application
    Filed: February 6, 2007
    Publication date: March 6, 2008
    Applicant: Amgen, Inc.
    Inventors: Thomas Boone, Huimin Li, Michael Mann
  • Novel Cdk11 molecules and uses thereof
    Publication number: 20080050734
    Abstract: The present invention relates to a novel serine threonine kinase. The invention also relates to vector, host cells, antibodies and recombinant methods for producing the Cdk11 polypeptide. In addition, the invention discloses therapeutic, diagnostic and research utilities for Cdk11 and related products.
    Type: Application
    Filed: January 26, 2007
    Publication date: February 28, 2008
    Applicant: AMGEN INC.
    Inventors: Steven Coats, Peter Yakowec, Marc Payton